The second annual symposium on the future of lung cancer: A translational focus

Ranee Mehra

Research output: Contribution to journalArticle

Abstract

Lung cancer continues to be a leading cause of death in the US, and in its most advanced stages remains incurable. Cytotoxic chemotherapies have been the standard of care for the treatment of unresectable disease. However, recent advances in the development of epidermal growth factor receptor (EGFR) inhibitors have led the way to a new generation of targeted biological agents. During the second annual symposium entitled 'the future of lung cancer: a translational focus', which was sponsored by the Physician's Education Resource, new strategies for the treatment of lung cancer were discussed. Besides the role of EGFR inhibitors, potential targets include the angiogenesis pathway; other growth factor pathways, such as phosphoinositol-3 kinase/Akt and Raf-MEK; the 26S proteasome, the histone deacetylase mechanism; and the TNF-related apoptosis-inducing factor receptors. Agents that are directed against these targets are all in varying stages of clinical development. As more is learned about their mechanisms of action and clinical spectrum of activity, the author anticipates their incorporation into novel regimens with enhanced activity against lung cancer.

Original languageEnglish (US)
Pages (from-to)475-480
Number of pages6
JournalExpert Opinion on Therapeutic Targets
Volume10
Issue number3
DOIs
StatePublished - Jun 2006
Externally publishedYes

Fingerprint

Epidermal Growth Factor Receptor
Lung Neoplasms
Apoptosis Inducing Factor
Histone Deacetylases
Chemotherapy
Mitogen-Activated Protein Kinase Kinases
Biological Factors
Intercellular Signaling Peptides and Proteins
Phosphotransferases
Education
raf Kinases
Standard of Care
Cause of Death
Physicians
Drug Therapy
Therapeutics
ATP dependent 26S protease

Keywords

  • Lung cancer
  • Molecular-targeted therapy
  • Tyrosine kinase inhibitor (TKI)

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology
  • Drug Discovery
  • Clinical Biochemistry

Cite this

The second annual symposium on the future of lung cancer : A translational focus. / Mehra, Ranee.

In: Expert Opinion on Therapeutic Targets, Vol. 10, No. 3, 06.2006, p. 475-480.

Research output: Contribution to journalArticle

@article{b85ad5336956456cab0c4663f81611f9,
title = "The second annual symposium on the future of lung cancer: A translational focus",
abstract = "Lung cancer continues to be a leading cause of death in the US, and in its most advanced stages remains incurable. Cytotoxic chemotherapies have been the standard of care for the treatment of unresectable disease. However, recent advances in the development of epidermal growth factor receptor (EGFR) inhibitors have led the way to a new generation of targeted biological agents. During the second annual symposium entitled 'the future of lung cancer: a translational focus', which was sponsored by the Physician's Education Resource, new strategies for the treatment of lung cancer were discussed. Besides the role of EGFR inhibitors, potential targets include the angiogenesis pathway; other growth factor pathways, such as phosphoinositol-3 kinase/Akt and Raf-MEK; the 26S proteasome, the histone deacetylase mechanism; and the TNF-related apoptosis-inducing factor receptors. Agents that are directed against these targets are all in varying stages of clinical development. As more is learned about their mechanisms of action and clinical spectrum of activity, the author anticipates their incorporation into novel regimens with enhanced activity against lung cancer.",
keywords = "Lung cancer, Molecular-targeted therapy, Tyrosine kinase inhibitor (TKI)",
author = "Ranee Mehra",
year = "2006",
month = "6",
doi = "10.1517/14728222.10.3.475",
language = "English (US)",
volume = "10",
pages = "475--480",
journal = "Expert Opinion on Therapeutic Targets",
issn = "1472-8222",
publisher = "Informa Healthcare",
number = "3",

}

TY - JOUR

T1 - The second annual symposium on the future of lung cancer

T2 - A translational focus

AU - Mehra, Ranee

PY - 2006/6

Y1 - 2006/6

N2 - Lung cancer continues to be a leading cause of death in the US, and in its most advanced stages remains incurable. Cytotoxic chemotherapies have been the standard of care for the treatment of unresectable disease. However, recent advances in the development of epidermal growth factor receptor (EGFR) inhibitors have led the way to a new generation of targeted biological agents. During the second annual symposium entitled 'the future of lung cancer: a translational focus', which was sponsored by the Physician's Education Resource, new strategies for the treatment of lung cancer were discussed. Besides the role of EGFR inhibitors, potential targets include the angiogenesis pathway; other growth factor pathways, such as phosphoinositol-3 kinase/Akt and Raf-MEK; the 26S proteasome, the histone deacetylase mechanism; and the TNF-related apoptosis-inducing factor receptors. Agents that are directed against these targets are all in varying stages of clinical development. As more is learned about their mechanisms of action and clinical spectrum of activity, the author anticipates their incorporation into novel regimens with enhanced activity against lung cancer.

AB - Lung cancer continues to be a leading cause of death in the US, and in its most advanced stages remains incurable. Cytotoxic chemotherapies have been the standard of care for the treatment of unresectable disease. However, recent advances in the development of epidermal growth factor receptor (EGFR) inhibitors have led the way to a new generation of targeted biological agents. During the second annual symposium entitled 'the future of lung cancer: a translational focus', which was sponsored by the Physician's Education Resource, new strategies for the treatment of lung cancer were discussed. Besides the role of EGFR inhibitors, potential targets include the angiogenesis pathway; other growth factor pathways, such as phosphoinositol-3 kinase/Akt and Raf-MEK; the 26S proteasome, the histone deacetylase mechanism; and the TNF-related apoptosis-inducing factor receptors. Agents that are directed against these targets are all in varying stages of clinical development. As more is learned about their mechanisms of action and clinical spectrum of activity, the author anticipates their incorporation into novel regimens with enhanced activity against lung cancer.

KW - Lung cancer

KW - Molecular-targeted therapy

KW - Tyrosine kinase inhibitor (TKI)

UR - http://www.scopus.com/inward/record.url?scp=33745477727&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33745477727&partnerID=8YFLogxK

U2 - 10.1517/14728222.10.3.475

DO - 10.1517/14728222.10.3.475

M3 - Article

C2 - 16706687

AN - SCOPUS:33745477727

VL - 10

SP - 475

EP - 480

JO - Expert Opinion on Therapeutic Targets

JF - Expert Opinion on Therapeutic Targets

SN - 1472-8222

IS - 3

ER -